Mirum Pharmaceuticals Financials
MIRM Stock | USD 46.65 1.50 3.32% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 4.23 | 4.4512 |
|
|
The financial analysis of Mirum Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Mirum Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Mirum | Select Account or Indicator |
Understanding current and past Mirum Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mirum Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Mirum Pharmaceuticals' assets may result in an increase in income on the income statement.
Mirum Pharmaceuticals Earnings Geography
Mirum Pharmaceuticals Stock Summary
Mirum Pharmaceuticals competes with Immunocore Holdings, Larimar Therapeutics, Kalvista Pharmaceuticals, Lyra Therapeutics, and Terns Pharmaceuticals. Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. Mirum Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 171 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US6047491013 |
CUSIP | 604749101 |
Location | California; U.S.A |
Business Address | 950 Tower Lane, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.mirumpharma.com |
Phone | 650 667 4085 |
Currency | USD - US Dollar |
Mirum Pharmaceuticals Key Financial Ratios
Return On Equity | -0.4 | ||||
Profit Margin | (0.33) % | ||||
Operating Margin | (0.14) % | ||||
Price To Sales | 7.29 X | ||||
Revenue | 186.37 M |
Mirum Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 146.7M | 240.9M | 294.7M | 352.9M | 646.6M | 679.0M | |
Other Current Liab | 9.3M | 14.0M | 32.0M | 54.2M | 77.4M | 81.3M | |
Other Liab | 36K | 47.7M | 129.9M | 144.9M | 166.6M | 174.9M | |
Net Tangible Assets | 130.3M | 172.1M | 101.5M | 83.1M | 95.5M | 103.3M | |
Net Debt | (136.3M) | (138.8M) | (28.7M) | (25.8M) | 21.8M | 22.9M | |
Retained Earnings | (69.9M) | (173.2M) | (257.2M) | (392.8M) | (556.2M) | (528.4M) | |
Accounts Payable | 3.4M | 3.2M | 9.2M | 8.7M | 7.4M | 5.9M | |
Cash | 140.0M | 142.1M | 31.3M | 28.0M | 286.3M | 300.6M | |
Other Assets | 324K | 3.2M | 101.8M | 101.4M | 1.0 | 0.95 | |
Capital Surpluse | 200.1M | 345.2M | 377.4M | 535.1M | 615.3M | 320.7M | |
Other Current Assets | 2.7M | 9.1M | 10.5M | 8.9M | 10.9M | 7.7M | |
Total Liab | 16.4M | 68.8M | 174.4M | 210.9M | 398.0M | 417.8M | |
Net Invested Capital | 130.3M | 172.1M | 120.2M | 142.0M | 555.1M | 582.8M | |
Total Current Assets | 119.4M | 236.4M | 166.6M | 190.2M | 387.5M | 211.2M | |
Net Working Capital | 106.3M | 217.9M | 124.0M | 125.5M | 300.5M | 169.3M | |
Short Term Debt | 397K | 1.3M | 1.4M | 1.9M | 2.2M | 1.3M |
Mirum Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Income | 2.2M | 1.6M | 366K | 3.9M | 12.1M | 12.7M | |
Interest Expense | 2.5M | 335K | 17.6M | 16.0M | 15.1M | 9.4M | |
Gross Profit | (324K) | (623K) | 17.2M | 64.7M | 139.3M | 146.3M | |
Operating Income | (54.7M) | (104.3M) | (173.4M) | (131.2M) | (109.2M) | (114.6M) | |
Ebit | (54.7M) | (102.9M) | (66.4M) | (126.1M) | (147.3M) | (140.0M) | |
Research Development | 43.0M | 81.6M | 131.4M | 106.8M | 102.6M | 86.0M | |
Cost Of Revenue | 324K | 623K | 1.9M | 12.4M | 47.0M | 49.4M | |
Income Before Tax | (52.5M) | (103.3M) | (84.0M) | (142.1M) | (162.4M) | (154.3M) | |
Net Income | (52.6M) | (103.3M) | (84.0M) | (135.7M) | (163.4M) | (155.2M) | |
Income Tax Expense | 21K | 6K | 37K | (6.4M) | 991K | 1.0M |
Mirum Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Investments | (127.8M) | 11.3M | (42.4M) | 8.0M | (78.4M) | (82.4M) | |
Change In Cash | (40.0M) | 130.1M | (10.7M) | (3.3M) | 158.3M | 166.2M | |
Net Income | (52.6M) | (103.3M) | (84.0M) | (135.7M) | (163.4M) | (155.2M) | |
End Period Cash Flow | 12.0M | 142.1M | 131.3M | 128.0M | 286.3M | 300.6M | |
Change To Netincome | 5.7M | 12.6M | 23.1M | 27.0M | 31.1M | 19.8M |
Mirum Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mirum Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Mirum Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mirum Pharmaceuticals competition to find correlations between indicators driving Mirum Pharmaceuticals's intrinsic value. More Info.Mirum Pharmaceuticals is rated below average in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Mirum Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Mirum Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Mirum Pharmaceuticals Systematic Risk
Mirum Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mirum Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Mirum Pharmaceuticals correlated with the market. If Beta is less than 0 Mirum Pharmaceuticals generally moves in the opposite direction as compared to the market. If Mirum Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mirum Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mirum Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Mirum Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Mirum Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mirum Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mirum Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Mirum Pharmaceuticals November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mirum Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mirum Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mirum Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Mirum Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mirum Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 2.51 | |||
Information Ratio | (0.01) | |||
Maximum Drawdown | 12.25 | |||
Value At Risk | (4.31) | |||
Potential Upside | 3.88 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.